Anhui Anke BioTech Group - Asset Resilience Ratio
Anhui Anke BioTech Group (300009) has an Asset Resilience Ratio of 21.62% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 300009 working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2025)
This chart shows how Anhui Anke BioTech Group's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Anhui Anke BioTech Group assets under control.
Liquid Assets Composition Over Time
This chart breaks down Anhui Anke BioTech Group's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Anhui Anke BioTech Group long-term investment allocation to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.11 Billion | 21.62% |
| Total Liquid Assets | CN¥1.11 Billion | 21.62% |
Asset Resilience Insights
- Good Liquidity Position: Anhui Anke BioTech Group maintains a healthy 21.62% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Anhui Anke BioTech Group Industry Peers by Asset Resilience Ratio
Compare Anhui Anke BioTech Group's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH |
Biotechnology | 63.98% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 62.24% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
|
Wecome Pharmaceutical Co Ltd
SHE:300878 |
Biotechnology | 0.67% |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX |
Biotechnology | 86.66% |
|
Relmada Therapeutics Inc
NASDAQ:RLMD |
Biotechnology | 95.25% |
|
MediWound Ltd
F:M8W |
Biotechnology | 56.04% |
Annual Asset Resilience Ratio for Anhui Anke BioTech Group (2011–2025)
The table below shows the annual Asset Resilience Ratio data for Anhui Anke BioTech Group.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 21.49% | CN¥1.19 Billion ≈ $174.42 Million |
CN¥5.55 Billion ≈ $811.80 Million |
-0.80pp |
| 2024-12-31 | 22.29% | CN¥1.14 Billion ≈ $167.51 Million |
CN¥5.14 Billion ≈ $751.46 Million |
-1.86pp |
| 2023-12-31 | 24.15% | CN¥1.20 Billion ≈ $174.95 Million |
CN¥4.95 Billion ≈ $724.45 Million |
+4.35pp |
| 2022-12-31 | 19.80% | CN¥842.91 Million ≈ $123.34 Million |
CN¥4.26 Billion ≈ $622.91 Million |
-2.15pp |
| 2021-12-31 | 21.95% | CN¥805.43 Million ≈ $117.86 Million |
CN¥3.67 Billion ≈ $536.90 Million |
+3.63pp |
| 2020-12-31 | 18.32% | CN¥646.45 Million ≈ $94.60 Million |
CN¥3.53 Billion ≈ $516.39 Million |
+12.81pp |
| 2019-12-31 | 5.51% | CN¥177.85 Million ≈ $26.02 Million |
CN¥3.23 Billion ≈ $472.10 Million |
+3.34pp |
| 2017-12-31 | 2.17% | CN¥48.99 Million ≈ $7.17 Million |
CN¥2.25 Billion ≈ $329.85 Million |
-0.98pp |
| 2016-12-31 | 3.15% | CN¥62.00 Million ≈ $9.07 Million |
CN¥1.97 Billion ≈ $287.58 Million |
-5.53pp |
| 2015-12-31 | 8.68% | CN¥120.80 Million ≈ $17.68 Million |
CN¥1.39 Billion ≈ $203.54 Million |
-8.87pp |
| 2014-12-31 | 17.55% | CN¥160.71 Million ≈ $23.52 Million |
CN¥915.58 Million ≈ $133.98 Million |
-9.94pp |
| 2013-12-31 | 27.50% | CN¥206.18 Million ≈ $30.17 Million |
CN¥749.81 Million ≈ $109.72 Million |
+3.80pp |
| 2012-12-31 | 23.70% | CN¥154.72 Million ≈ $22.64 Million |
CN¥652.93 Million ≈ $95.54 Million |
-10.02pp |
| 2011-12-31 | 33.71% | CN¥203.50 Million ≈ $29.78 Million |
CN¥603.65 Million ≈ $88.33 Million |
-- |
About Anhui Anke BioTech Group
Anhui Anke Biotechnology (Group) Co., Ltd. engages in the biopharmaceutical industry in China and internationally. It offers human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterferon name… Read more